3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
549
Carcinoma, Non-Small-Cell Lung
509
Prostatic Neoplasms
333
Colorectal Neoplasms
270
Multiple Myeloma
266
Neoplasms
262
Leukemia, Myeloid, Acute
221
Squamous Cell Carcinoma of Head and Neck
214
Lung Neoplasms
207
Neoplasm Metastasis
203
Carcinoma, Hepatocellular
197
Melanoma
172
Triple Negative Breast Neoplasms
171
Pancreatic Neoplasms
170
Recurrence
152
Ovarian Neoplasms
149
Lymphoma
139
Brain Neoplasms
133
Glioblastoma
132
Sarcoma
130
Carcinoma, Renal Cell
126
Leukemia, Lymphocytic, Chronic, B-Cell
125
Head and Neck Neoplasms
124
Stomach Neoplasms
122
Lymphoma, Large B-Cell, Diffuse
122
Rectal Neoplasms
107
Precursor Cell Lymphoblastic Leukemia-Lymphoma
105
Myelodysplastic Syndromes
102
Uterine Cervical Neoplasms
100
Urinary Bladder Neoplasms
100
Interventions
mirdametinib
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphatic Abnormalities
×
1 year
×
Clear all
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled